Dr. Chap recalls the newest cancer medications being studied in the clinical environment.
Well, there are several drugs that we have currently in clinical drug development, which at any time ranges perhaps from 20 to 30 clinical trials, and most of these trials really are working with the goal of using a therapy that interrupts a signal that is making that cancer cell a cancer cell.
Why is it a cancer? It’s because it is not dying when it’s supposed to. So one cell becomes two, becomes four, becomes eight. So our interest is in drugs that interrupt that pathway, not just randomly killing the cancer cells and normal cells in the body, but something specifically targeted to what’s driving that cancer cell to be a cancer.
About Dr. Linnea Chap, M.D.:
Linnea Chap, M.D., is a medical oncologist with an interest in breast cancer treatment. She has been published multiple times and has led several breast and ovarian cancer treatment protocols, including the pioneering use of novel biologic agents such as Herceptin and Avastin. In 2001, Dr. Chap was named, one of “America’s Top Breast Cancer Doctors” by Redbook. Annually, she has also been listed as one of “America’s Top Doctors for Cancer,” published by Michael Connelly. Recognized for her teaching and speaking skills, Dr. Chap has a national reputation where she is frequently called on to speak on the most recent advances in breast cancer treatment.